Page 20 of 31: studies 191 to 200 of 308, newest first. Back to the psilocybin for anxiety overview
Cambridge University Press eBooks March 20, 2022 Timmen Cermak
Jackson was bored with his massage therapy practice and was looking for something more interesting to do. Cannabis legalization had reawakened his interest in the use of natural, psychoactive substances as healing and spiritual agents. A once-a-month user of cannabis, he was enthusiastic about Johns Hopkins University’s research on the potential mental health benefits of psilocybin, the...
Australian & New Zealand Journal of Psychiatry March 12, 2022 Steve Kisely, Mark Connor, Andrew A Somogyi et al. 36 citations
Objectives: There is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed,...
Journal of Fungi March 11, 2022 Elaine Meade, Sarah Hehir, Neil J. Rowan et al. 24 citations
Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these...
Frontiers in Psychology March 4, 2022 Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan 27 citations
Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA), has demonstrated promise in treatment of post-traumatic stress disorder (PTSD), anxiety, addiction, and treatment-resistant depression. Psychedelic-assisted psychotherapy (PP) represents a unique psychopharmacological model that...
medRxiv March 2, 2022 Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al. preprint
Abstract Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in relatively low response rates (average range: 51 - 58%). Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy...
Journal of Psychopharmacology March 1, 2022 Max Wolff, Lea J. Mertens, Marie Walter et al. 57 citations
Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...
Journal of Psychoactive Drugs February 28, 2022 Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al. 47 citations
There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the "Psychedelic Renaissance." This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain...
Journal of Xenobiotics February 7, 2022 Maurizio Coppola, Francesco Bevione, Raffaella Mondola 29 citations
Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s...
Cureus February 5, 2022 Shawn Ziff, Benjamin Stern, Gregory D. Lewis et al. 32 citations
Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other classic psychedelics (5HT-2A...
Journal of Psychopharmacology February 1, 2022 Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. 419 citations
Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This...